Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 3/20 | 0.44 |
| ▸ | CRY1 | Q16526 | 4/20 | 0.40 |
| ▸ | CRY2 | Q49AN0 | 4/20 | 0.40 |
| ▸ | HTR5A | P47898 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622572 | 0.88 | PER2 (0.47) | PER2CRY1CRY2PIK3CD | |
| SCHEMBL10908865 | 0.76 | PER2 (0.37) | PER2CRY1CRY2 | |
| SCHEMBL5837907 | 0.76 | — | — | |
| SCHEMBL4609193 | 0.71 | PER2 (0.35) | PER2CRY1CRY2HTR5A | |
| SCHEMBL13672147 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL12477923 | 0.67 | HTR5A (0.36) | PER2CRY1CRY2HTR5A | |
| SCHEMBL24819121 | 0.64 | PIK3CD (0.31) | PIK3CD | |
| SCHEMBL11936466 | 0.64 | PER2 (0.40) | PER2CRY1CRY2 | |
| SCHEMBL7850143 | 0.64 | CRY1 (0.43) | PER2CRY1CRY2PIK3CD | |
| SCHEMBL13622575 | 0.64 | PER2 (0.45) | PER2CRY1CRY2HTR5APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391077-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2019-08-27 | — | — | US | disclosed |
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | Oncoarendi Therapeutics S.A. (PL) | 2017-11-09 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7619094-B2 | Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | SCHERING CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391077-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, ARGLU1 | PER2 2877/4885CRY1 3963/4885CRY2 3435/4885 |
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | PREP, PRSS1, P4HB | PER2 1963/4885CRY1 2678/4885CRY2 3659/4885 |
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | ARG1, ARG2, ARGLU1 | PER2 2877/4885CRY1 3963/4885CRY2 3435/4885 |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | PER2 2627/4885CRY1 2971/4885CRY2 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.